A new Gilead analysis indicates remdesivir can reduce death but company says finding 'requires confirmation'

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 22 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 97%

Malaysia News News

Malaysia Malaysia Latest News,Malaysia Malaysia Headlines

Gilead up in premarket as it says it's presented new remdesivir data

Shares of Gilead Sciences Inc.

gained 2.0% in premarket trading on Friday after the drugmaker disclosed findings from a new analysis of previously disclosed clinical trial data that found the experimental therapy remdesivir can reduce the risk of mortality in COVID-19 patients by 62%, when compared to the standard of care. Gilead said the mortality data point is"an important finding that requires confirmation in prospective clinical trials.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

HCL works!

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in MY

Malaysia Malaysia Latest News, Malaysia Malaysia Headlines